| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
9,230,000 |
| Market
Cap: |
3.60(M) |
| Last
Volume: |
426,351 |
Avg
Vol: |
425,187 |
| 52
Week Range: |
$0.39 - $0.39 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company working to develop cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The transcriptional regulation program is evaluating fadraciclib, a Cyclin Dependent Kinase 2/9 (CDK2/9) inhibitor, in solid tumors and hematological malignancies. The anti-mitotic program is evaluating CYC140, a Polo-Like-Kinase 1(PLK 1) inhibitor, in cancers. CDKs are a family of enzymes discovered as regulators of the cell cycle. PLK1 is a serine/threonine kinase with a central role in cell division, or the mitotic phase of the cell cycle, and is a regulator of the DNA damage checkpoint.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
7,956 |
7,956 |
7,956 |
| Total Buy Value |
$0 |
$26,374 |
$26,374 |
$26,374 |
| Total People Bought |
0 |
2 |
2 |
2 |
| Total Buy Transactions |
0 |
2 |
2 |
2 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Morgan Stanley |
10% Owner |
– – • |
2008-08-01 |
4 |
B |
$1.89 |
$58,968 |
I/I |
31,200 |
3,026,324 |
1.5 |
- |
|
| Morgan Stanley |
10% Owner |
– – • |
2008-07-01 |
4 |
S |
$1.91 |
$66,086 |
I/I |
(34,600) |
3,026,324 |
|
- |
|
| Morgan Stanley |
10% Owner |
– – • |
2008-07-01 |
4 |
B |
$1.91 |
$66,086 |
I/I |
34,600 |
3,060,924 |
1.5 |
- |
|
| Chiao Judy |
V.P., Clin. Dev. & Reg. Aff. |
• – – |
2008-06-09 |
4 |
B |
$2.11 |
$4,272 |
D/D |
2,000 |
48,168 |
2.66 |
- |
|
| Uprichard David C |
Director |
– • – |
2008-06-05 |
4 |
B |
$1.93 |
$9,659 |
D/D |
5,000 |
25,306 |
2.39 |
- |
|
| Rombotis Spiro |
President & C.E.O. |
• • – |
2008-06-05 |
4 |
B |
$2.02 |
$10,090 |
D/D |
5,000 |
401,648 |
2.81 |
- |
|
| Rombotis Spiro |
President & C.E.O. |
• • – |
2008-06-04 |
4 |
B |
$2.04 |
$10,180 |
D/D |
5,000 |
396,648 |
2.81 |
- |
|
| Morgan Stanley |
10% Owner |
– – • |
2008-06-02 |
4 |
S |
$2.09 |
$49,951 |
I/I |
(23,900) |
3,026,324 |
|
- |
|
| Morgan Stanley |
10% Owner |
– – • |
2008-06-02 |
4 |
B |
$2.09 |
$49,951 |
I/I |
23,900 |
3,050,224 |
1.5 |
- |
|
| Mcbarron Paul |
E.V.P., Finance & C.O.O. |
• • – |
2008-05-22 |
4 |
B |
$2.25 |
$4,388 |
D/D |
1,950 |
76,054 |
2.73 |
- |
|
| Rombotis Spiro |
President & C.E.O. |
• • – |
2008-05-21 |
4 |
B |
$2.30 |
$17,235 |
D/D |
7,500 |
391,648 |
2.81 |
- |
|
| Rombotis Spiro |
President & C.E.O. |
• • – |
2008-05-20 |
4 |
B |
$2.35 |
$11,755 |
D/D |
5,000 |
384,648 |
2.81 |
- |
|
| Rombotis Spiro |
President & C.E.O. |
• • – |
2008-05-15 |
4 |
B |
$2.49 |
$12,430 |
D/D |
5,000 |
379,648 |
2.81 |
- |
|
| Rombotis Spiro |
President & C.E.O. |
• • – |
2008-05-14 |
4 |
B |
$2.64 |
$26,350 |
D/D |
10,000 |
374,648 |
2.81 |
- |
|
| Morgan Stanley |
10% Owner |
– – • |
2008-05-07 |
4 |
S |
$2.84 |
$4,544 |
I/I |
(1,600) |
3,026,324 |
|
- |
|
| Morgan Stanley |
10% Owner |
– – • |
2008-05-02 |
4 |
S |
$2.90 |
$8,700 |
I/I |
(3,000) |
3,027,924 |
|
- |
|
| Morgan Stanley |
10% Owner |
– – • |
2008-05-01 |
4 |
B |
$2.94 |
$187,278 |
I/I |
63,700 |
3,030,924 |
1.5 |
- |
|
| Morgan Stanley |
10% Owner |
– – • |
2008-05-01 |
4 |
S |
$2.94 |
$187,278 |
I/I |
(63,700) |
2,967,224 |
|
- |
|
| Morgan Stanley |
10% Owner |
– – • |
2008-03-20 |
4 |
S |
$3.09 |
$120,201 |
I/I |
(38,900) |
3,030,924 |
|
- |
|
| Rombotis Spiro |
President & C.E.O. |
• • – |
2008-03-20 |
4 |
B |
$2.75 |
$7,150 |
D/D |
2,600 |
364,648 |
2.81 |
- |
|
| Reyes Gregory |
Senior VP, Research |
• – – |
2008-03-20 |
4 |
B |
$2.90 |
$8,700 |
D/D |
3,000 |
3,000 |
2.74 |
- |
|
| Rombotis Spiro |
President & C.E.O. |
• • – |
2008-03-19 |
4 |
B |
$2.75 |
$8,800 |
D/D |
3,200 |
362,048 |
2.81 |
- |
|
| Womelsdorf Dr John Francis |
VP, Business Development |
• – – |
2008-03-18 |
4 |
B |
$2.83 |
$14,444 |
D/D |
5,000 |
2,100 |
2.74 |
- |
|
| Deerfield Special Situations Fund International Lt |
10% Owner |
– – • |
2008-03-11 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
2,126,578 |
|
- |
|
| Morgan Stanley |
10% Owner |
– – • |
2008-03-04 |
4 |
S |
$3.87 |
$797,259 |
I/I |
(195,700) |
3,069,824 |
|
- |
|
281 Records found
|
|
Page 6 of 12 |
|
|
